p53 mutations are common genetic alterations in human cancer. Gene transfer of a wild-type (wt) p53 gene reverses the loss of normal p53 function in vitro and in vivo. A phase I dose escalation study of single intratumoral (i.t.) injection of a replication-defective adenoviral expression vector containing wt p53 was carried out in patients with metastatic melanoma or breast cancer with increased p53 protein immunoreactivity in pretreatment tumor biopsies. The biological activity of the injected wt p53 was assayed by reverse transcriptase-polymerase chain reaction in tumor tissue. A total of six (five melanoma and one breast adenocarcinoma) patients were treated at dose levels dependent upon tumor size/dose escalation sequence. Five of six patients became positive for the transfer of wt p53 into tumor tissue 2 days after injection of the vector. Of the four patients assayed, all developed anti-adenoviral antibodies. Adverse reactions associated with i.t. injection were mild, with no obvious correlation between the incidence, severity, or relationship of the events and drug dose. p53 gene therapy by i.t. injection of a replication-defective adenoviral expression vector is safe, feasible, and biologically effective (with respect to transduction frequency) in patients with either metastatic melanoma or breast cancer.
M
utations of the tumor suppressor gene p53 are detected in ϳ50% of colon and non-small cell lung cancers (NSCLCs) [1] [2] [3] and in 20 -25% of breast cancers, 4 with missense mutations within the DNA binding domain being the most common gene alteration observed. 5 The resultant defective protein accumulates intracellularly at high concentrations, 6 where the loss of a functional p53 protein impairs both cell cycle control and DNA damage repair mechanisms. 7 Mice with a homozygous deletion of p53 have a greatly enhanced susceptibility to early cancer development. 8 In humans, a familial germline mutation in p53 (Li-Fraumeni syndrome) resulting in increased breast cancer, sarcomas, and other neoplasms has been described. 9, 10 Also, mutations affecting p53 may curtail the apoptosis induced by several cytotoxic agents or radiation. 11, 12 Structural alterations in the p53 gene of tumors in NSCLC are associated with a worse prognosis. [13] [14] [15] A recent study reported induction of apoptosis and tumor regression in patients with advanced NSCLC after injection of a retroviral vector containing wild-type (wt) p53 into tumors. 16 However, although vector sequences were detected in posttreatment biopsies by DNA polymerase chain reaction (PCR) or in situ hybridization, there was no demonstration of transgene expression. Intratumoral (i.t.) injection of a replication-deficient adenoviral vector containing wt p53 17 demonstrated effective local disease control, as well as vector-specific wt p53 RNA expression, in four of six NSCLC patients.
The incidence of melanoma has increased rapidly worldwide. 18 The prognosis for patients with thin primary tumors is excellent after adequate surgical removal, but a significant proportion of these patients still develop distant metastases that ultimately lead to death. 19 The incidence of mutant p53 expression in primary melanoma is low; 20, 21 a much higher rate of p53 alterations is found for advanced lesions. 22 As melanoma is characterized by a resistance to cytotoxic drugs, the alteration of p53 mutant phenotypes might provide a reasonable addition to the present repertoire of therapeutic interventions. In addition, most melanomas ex-press the human Coxsackie and adenovirus receptors, which facilitate adenoviral entry into these tumor cells. 23 Breast cancer, which accounts for 18% of all cancer deaths in women, is the leading cause of death for women between the ages of 40 and 55. For patients with breast cancer, local control, in addition to control of distant metastases, is one of the common treatment approaches undertaken. The mutant p53 genotype has been identified in 20 -30% of all patients with breast cancer 24 and has prognostic implications. 25 Introduction of the wt p53 phenotype in human breast cancer cell lines has lead to suppression of tumor cell growth in cell lines. 26, 27 After the delivery of normal p53 via liposomes, tumor regressions and decreased metastatic spread occurred in xenografts of a p53 mutant human breast cancer in athymic mice. 28 Regression of xenografts derived from three breast carcinoma lines has also been reported in severe combined immunodeficient and athymic mice after the injection of the wt p53 adenoviral construct (SCH 58500) used in the present study. 29 A phase I study was performed to examine the ability to alter the p53 phenotype in cutaneous tumors from patients with melanoma or breast cancer after the injection of a wt p53 contained in a replication-defective adenovirus vector. This vector has been successfully used in NSCLC patients to achieve local control of the tumor.
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PATIENTS AND METHODS
Patients
All patients enrolled in the study either had histologically confirmed cutaneous or subcutaneous recurrence of metastatic melanoma at least 5 cm from the primary scar (five patients) or breast adenocarcinoma (one patient) for which curative treatment alternatives did not exist, with evidence of enhanced p53 protein levels in the tumor tissue. Evidence of enhanced p53 protein levels was determined by immunohistochemical (IHC) detection of strong nuclear p53 immunoreactivity by monoclonal antibodies (mAbs) Pab 1801 and/or Pab 240 (PharMingen, San Diego, Calif) in at least 10% of the tumor cells. A positive reaction served as a surrogate marker of mutant p53 status. 6 Currently, it is known that IHC gives false-positive rates of up to 30% and false-negative rates of up to 10%, and that sequencing for p53 status is the more accurate method. 30, 31 However, when this study was planned, these findings were not generally accepted. Because the primary objective of this study was transgene expression and safety, and immunohistochemistry is a rapid test and was readily available at all study sites, patients were enrolled based on IHC rather than the more stringent technology of gene sequencing. Staining of paraffinembedded tissue was performed using a streptavidin-biotin detection procedure, and reactivity was visualized by reaction with 3,3Ј diaminobenzidine. Sections were scored as negative if Ͻ10% of tumor cells stained positive with the aforementioned mAbs.
Additional inclusion criteria were as follows: Karnofsky performance status of Ն70; age of 18 -75 years; absence of clinically relevant hematological, hepatic, or renal insufficiency; and a life expectancy of at least 3 months. Exclusion criteria included the following: pregnant or lactating women; fertile males or females not practicing medically acceptable contraception for at least 6 months after study treatment; uncontrolled serious infections; seropositivity for the HIV; prior local antitumoral therapy directed against cutaneous or subcutaneous lesions; systemic antitumoral therapy within 28 days of study medication; or the receipt of immunosuppressive or corticosteroid treatment within the last 3 months before entry into the study. Acute adenoviral infection, as determined by enzyme-linked immunosorbent assay (ELISA) screening, was ruled out within 24 hours of therapy. All patients gave written informed consent.
Study design
This was a multicenter, open-label, single-dose, phase I dose escalation study. One patient was treated at each dose level, and dose escalation was continued until two consecutive dose levels confirmed biological activity of the treatment, as determined by the presence of wt p53 using reverse transcriptase (RT)-PCR in at least two patients at the same dose level, or until any significant dose-limiting toxicity was encountered. Each patient was followed weekly for 28 days, with day 1 being the date of treatment. Upon completion of the observation period, all patients were followed at the study centers at regular intervals. The consent form and the protocol were approved by the ethics committee of the participating center, the National Health Authorities (Switzerland), the Ministry of Environment (The Netherlands), and the Medical Products Agency (Sweden). The study was performed according to the Declaration of Helsinki and according to the principles of Good Clinical Practice. All biosafety precautions and procedures required by the Institutional Biosafety Committee and local regulatory authorities were observed.
Study endpoints
The primary objectives of the study were to determine the safety, feasibility, and biological activity of a single i.t. injection of SCH 58500, as determined by RT-PCR detection of vectorspecific wt p53 RNA sequences in posttreatment tumor biopsies. The secondary objective of the study was to assess any clinical evidence of the antitumoral efficacy of i.t. SCH 58500 injection in patients with either metastatic melanoma or breast cancer.
Staging procedures
At baseline and on day 28, all patients underwent staging of all sites of disease and determination of tumor dimensions for all sites of measurable disease, defined as any lesion with a perpendicular dimension of Ն0.5 cm ϫ Ն0.5 cm, as assessed by physical examination and/or radiographic imaging scan. Patients underwent computed tomography scans of the chest and abdomen/pelvis and bone scans at baseline and at day 28 if needed to evaluate all sites of disease for staging purposes.
Treatment
SCH 58500 (rAd/p53) is a replication-defective recombinant adenovirus type 5-containing wt p53 cDNA under the control of the human cytomegalovirus immediate early gene promoter. 27, 32, 33 SCH 58500 was manufactured under current good manufacturing practice compliance in validated plant facilities under strict environmental monitoring and control conditions by Schering-Plow Werthenstein Chemie AG (Schachen, Switzerland) 17 and was supplied in vial strengths of 1 ϫ 10 8 plaque-forming units (PFU)/mL and 1 ϫ 10 9 PFU/mL (7.5 ϫ 10 10 particles/mL and 7.5 ϫ 10 11 particles/mL). All patients were treated once with a calculated total dose of SCH 58500 (based on tumor size) divided and administered as four injections of equal volume, with one injection given per tumor quadrant within the tumor at its perimeter. The absolute dose levels used per patient were: 2 ϫ 10 7 PFU (0.2 mL), 3 ϫ 10 7 PFU (0.3 mL), 5 ϫ 10 7 PFU (0.5 mL), 3 ϫ 10 8 PFU (0.3 mL), 4 ϫ 10 8 PFU (0.4 mL), and 5 ϫ 10 8 PFU (5 mL). The maximum diameters of the tumors given these injections were: 1.3 cm, 2.5 cm, 4.5 cm, 2.1 cm, 3.6 cm, and 4.7 cm, respectively. After treatment, all patients were hospitalized in single rooms in an isolation unit for at least 72 hours or until adenovirus shedding by the patients became negative. All patients underwent a 5-to 8-mm punch biopsy of the treated tumor lesion either 24 or 48 hours after injection of SCH 58500 to confirm transgene expression.
The World Health Organization grading system was used to grade the severity of acute and subacute adverse events. For adverse events not covered by the World Health Organization grading system, the following definitions were used: mild (awareness of sign, symptom, or event, but easily tolerated), moderate (discomfort enough to cause interference with usual activity; may warrant intervention), severe (incapacitating, with inability to perform usual activities or significantly effected clinical status; warranting intervention), and life-threatening (immediate risk of death).
Detection of wt p53 gene transfer
Expression of vector-specific wt p53 RNA was assessed in posttreatment biopsies by means of RT-PCR according to previously published methods. 32 In brief, total cellular RNA was isolated from homogenized tumor biopsies and reverse transcribed into cDNA. PCR was performed for 28 cycles on all samples. Samples from two patients with negative results after 28 cycles were also run for 45 cycles to increase sensitivity. The vector-encoded p53 cDNA was amplified using specific primers, one within the Ad2 tripartite leader (at the 5Ј end of the mRNA), and the second within the p53 coding region. Parallel PCRs using primers specific for human ␤-actin served as controls for the RNA extraction as well as for cDNA synthesis. Semiquantitation was carried out for vector-encoded p53 cDNA as well as for the human ␤-actin through the use of DNA "mimics" specific for each region. The mimic carried sequences at its ends, which allowed it to be amplified by the same primers used to amplify the target sequence. Addition of a known concentration of mimic to a given reaction enabled the determination of the relative amount of each cDNA present. Quantification of the amplified DNA bands was performed on a Molecular Dynamics FluorImager (Molecular Dynamics, Sunnyvale, Calif).
Virology studies
Adenovirus shedding and excretion was assessed in a patient's urine and stool by means of a commercially available ELISA kit (Adenoclone; Cambridge Biotech, Worcester, Mass). In addition, serum, nasal, urine, and stool samples were assayed to detect the presence of adenovirus using a fluorescenceactivated cell sorter (FACS) assay and a PCR assay (if necessary). Briefly, samples from patients recovered at pretreatment and at 2 and 3 days postinjection were incubated with human embryonic kidney 293 cells for 48 hours. The cells were fixed and reacted with an anti-adenovirus type 5 antibody (Ab) followed by FACS sorting. Samples deemed to be positive for infectious activity were to be reassayed after incubation with 293 cells for 24 -48 hours followed by PCR assay with paired primers specific for SCH 58500. An ELISA system was established to detect serum Abs against SCH 58500, which also detects cross-reacting Abs against wt adenoviruses. In brief, microtiter plates were coated overnight with SCH 58500 and subsequently washed and blocked with bovine serum albumin. After initially diluting serum samples 1/40 in phosphate-buffered saline/1% bovine serum albumin/0.05% Tween, a further set of seven serial 2-fold dilutions of serum samples was incubated overnight in the microtiter plates. A positive control and pooled normal sera were also assayed on each plate. After washing, anti-SCH 58500 Abs were detected by a reaction with biotin-labeled protein A/G (Jackson Immunoresearch Labs, West Grove, Penn) followed by streptavidinlabeled horseradish peroxidase, and were visualized by reaction with tetramethyl benzidine. Samples were considered positive for the presence of anti-SCH 58500 Abs if the ratio of the mean optical densities (ODs) of the sample dilutions versus the mean ODs of the normal human serum dilutions was above the threshold value of 0.28. Also, patients were considered positive for the development of anti-SCH 58500 Abs if the posttreatment sample was positive and there was at least a 2-fold increase in mean OD compared with pretreatment values.
Anti-adenovirus serum neutralizing Ab assays were performed using the Saos-2 antiproliferative assay, which measures the proliferation of the human osteosarcoma Saos-2 line in vitro. The assay measures the neutralization of adenovirus by anti-adenovirus serum Abs by comparing the proliferation of cells incubated with adenovirus and serum with the proliferation of unexposed cells. The following criteria were used to assess the reactivity of samples: a value of 0 -10% of control was considered a high positive for the presence of serum neutralizing Abs; 10% to Ͻ75% of control was considered positive; 75% to Ͻ85% of control was considered low positive; and Ͼ85% of control was considered negative for the presence of serum neutralizing Abs.
RESULTS
Wt p53 gene transfer
A total of six patients were enrolled in the study between February 18, 1997 and June 30, 1997. The baseline characteristics of these patients are shown in Table 1 . All patients had detectable levels of p53 protein in their tumors as determined by positive reactivity with mAbs Pab 1801 or Pab 240 (not detectable in normal tissue by ICH methods).
All patients were treated by a single i.t. injection of SCH 58500 (range of 2 ϫ 10 7 to 5 ϫ 10 8 PFU per patient). In all patients, sufficient amounts of RNA were recovered from posttreatment biopsies for analysis of transgene expression by RT-PCR. In five of six patients, expression of vector-specific wt p53 RNA sequences could be demonstrated in a non-dose-dependent manner in relation to SCH 58500 dose levels at 2 days postinjection ( Table 2 ). In one metastatic melanoma patient treated with 3 ϫ 10 7 PFU, wt p53 could not be detected even after 45 cycles of amplification. In occasional samples, there was a failure to detect ␤-actin (and p53); this was usually a result of small tissue samples that were procured for analysis.
Histopathology
In the patient given 5 ϫ 10 8 PFU, tumor necrosis and a dense cellular infiltration were noted 1 day after i.t. injection. Also, in the patient given 2 ϫ 10 7 PFU, the tumor cells were noted to be moderately infiltrated by small round cells at 1 day postinjection. Both of these patients were found to have the greatest vector-specific p53 expression. The patient who received 3 ϫ 10 8 PFU was found to have a mild reactive mononuclear infiltrate between tumor cells at 1 day postinjection. The patient who received 3 ϫ 10 7 PFU was found to have a mild lymphocytic-histiocytic perivascular infiltrate with eosinophils as well as infiltrate around the nerves; swelling of the endothelial cells was also present. This reaction was reported as an adverse event (injection site inflammation).
Clinical response and patient follow-up
Clinical results in relation to SCH 58500 dose levels and wt p53 RT-PCR status are summarized in Table 2 . One patient treated with 2 ϫ 10 7 PFU had stable disease at day 29 and was treated thereafter with chemotherapy (dacarbazine, cisplatin, interferon-␣, interleukin-2). One patient treated with 3 ϫ 10 7 PFU had stable disease at day 28, with two of three measured tumors unchanged in size and one of three measured tumors having a slight increase in size. One patient treated with 5 ϫ 10 7 PFU was hospitalized on day 25 and died on day 31 (30 days after receiving study drug) due to disease progression. The death was considered unrelated to the study drug, and the patient had discontinued from the study due to a general worsening of his medical condition. One patient treated with 3 ϫ 10 8 PFU had stable disease at day 27, but her condition deteriorated over the next 4 weeks. One patient treated with 4 ϫ 10 8 PFU had disease progression by day 29; multiple tumors, all 0.5 cm in diameter, appeared that surrounded the four tumors which were present at screening. One patient treated with 5 ϫ 10 8 PFU had stable disease at day 29.
Toxicity
In general, the toxicity of the i.t. injection of SCH 58500 was mild. The most common events reported by patients were edema, fever, fatigue, and tachycardia (Table 3) . There were no apparent correlations between the frequencies, severities, or relationships of the adverse events reported by these patients and the dose of SCH 58500 given. During the course of the study, there were no changes in laboratory grade from common toxicity criteria grade *The total number of patients for all categories combined will be Ͼ100% of all patients, because patients had Ͼ1 disease site or previous therapy. 0, 1, or 2 at baseline to grade 3 or 4 in any patient. In addition, there were few clinically relevant changes in vital signs during the course of the study. Both reports of tachycardia were considered to be mild in severity. One patient (receiving 5 ϫ 10 7 PFU) had an increase in heart rate from 80 beats per minute (bpm) at day 23 to 120 bpm at day 31, with no follow-up due to the patient's death on day 31. The second patient (receiving 3 ϫ 10 8 PFU) had an increase in heart rate from 89 bpm before injection to 112 bpm at 4 hours postinjection, with a continued increased rate (116 bpm) up to day 66. There were no changes noted in electrocardiogram tracings from pre-to posttreatment for any patient.
Virology studies
In all patients, adenovirus shedding was assessed on a daily basis in urine and stool before treatment and for 48 hours posttreatment. All patients were confirmed to be negative for adenovirus shedding before treatment, and none were positive after treatment using ELISA. Serum, urine, stool, and nasal swab samples from patients receiving 3 ϫ 10 7 and 5 ϫ 10 8 PFU were also examined before treatment and for 48 hours after treatment with the FACS assay and found to be negative for adenovirus shedding.
The ELISA anti-adenovirus Abs assay showed that of four patients tested, all had previous exposure to natural adenovirus infections, as indicated by Ab titers of Ն1: 320 at the screening/preinjection visits ( Table 4 ). Three of the four patients developed increased Ab titers that met the protocol criteria for a response to SCH 58500 (Table 4 ). The anti-adenovirus neutralizing Ab assay (Saos-2) indicated that patients developed neutralizing Abs toward SCH 58500 (Table 5) . Of these patients, only the patient receiving 3 ϫ 10 8 PFU was positive for the presence of neutralizing Abs at screening. This patient also had the highest preinjection background level of anti-SCH 58500 Abs as detected by the ELISA method.
DISCUSSION
Most of the common human cancers are often associated with mutations of the tumor suppressor gene p53, underscoring its central role in the prevention of malignant transformation and tumor progression. The expression of so-called wt p53 within tumor cells, which should in theory restore the normal regulation of growth control to transformed cells, has become a goal for cancer gene therapy. Suppression of tumor cell growth using the p53 adenoviral construct described in this study has been found in p53 mutant or null cell lines derived from tumors from a variety of tissues, 27 and tumor suppression has been demonstrated in several xenograft experiments in vivo. 29 Recent reports have indicated the successful transfer of wt p53 cDNA as suggested by increased apoptosis, using a retroviral vector, into the tumors of patients with lung cancer, although transgene expression was not actually detected. 16 In the present study, i.t. expression of vector-specific wt p53 RNA, as detected as by RT-PCR, was used as the primary endpoint. Immunohistochemistry is inferior to sequencing, as the latter has been Mild Possible *Ongoing adverse event was still present at the lat visit (day 31). †Ongoing adverse event was still present at the last visit (day 29). ‡Ongoing adverse event was still present at the follow-up visit (day 66).
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shown to yield better prognostic information in patients with breast cancer. 30 An adenoviral expression vector system was chosen because of its established safety in clinical trials and its organotropism, 34 -40 and because of its capability to effect wt p53 gene transfer in vitro and in preclinical animal models. 27, 32 Unlike retroviruses, integration into the cell genome is not an obligate part of the adenoviral life cycle; rather, adenovirus DNA functions in the extrachromosomal portion of the cell's nucleus. 41 Thus, in comparison with retroviral vectors for gene delivery, this process has the therapeutic advantage of reducing the risk of insertional mutagenesis and reducing the chance that viral DNA will be active in cell progeny after cell division.
In the present study, i.t. transgene expression of wt p53 could be detected in tumor samples taken 48 hours posttreatment in five (four melanoma and one breast cancer) of six patients given SCH 58500, although it was only possible to quantify the level relative to ␤-actin in four patients due to the small amounts of tumor tissue recovered. Of the patients with quantifiable levels of vector-specific p53 sequences, the two patients with the most pronounced wt p53 expression also had protocol- ‡Samples are positive for the development of Abs capable of binding to SCH 58500 if, in the addition to the condition listed in the second footnote, there is at leat a 2-fold increase for the predose sample to the postdose sample.
§NA, not applicable. defined stable disease at day 28. However, the RT-PCR data need to be interpreted with caution, as patients did not exhibit a correlation of disease state with wt p53 level.
The introduction of vector-specific p53 adenoviral constructs into the patients could also be inferred from the increase in anti-adenovirus titers in three of four patients assayed as well as from an increase in antiadenovirus neutralizing Abs in all four patients tested. The induction of anti-SCH 58500 neutralizing Abs would have had no effect on the expression of wt p53 introduced by the adenoviral vector because the levels of these Abs were low initially and did not increase (days 7-8 for three of the four patients assayed) until after the samples for RT-PCR were taken (day 2). Earlier studies have indicated that recombinant adenovirus injected directly into the tumor is highly efficient for immunizing patients against the transgene despite anti-adenovirus responses. 42 Adenovirus shedding, which is a potential safety concern if genetic technology is to be used as a standard treatment, did not occur with any of the doses employed in this study. The use of a replication-deficient adenoviral vector also makes transmission of genetically engineered adenoviruses to other individuals very unlikely. In the present study, patients exhibited mild, generally unrelated side effects after exposure to SCH 58500, and no clinically significant toxicity was observed.
In conclusion, i.t. transgene expression of wt p53, as determined by adenovirus-mediated gene transfer, was shown to be safe and feasible in patients with advanced metastatic melanoma and breast cancer. This proof of concept study will lay the groundwork to support the development of p53 therapy in oncology.
